Ocular Safety and Usability Study for FYB203 PFS

NCT06708637 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration
Branch Retinal Vein Occlusion with Macular Edema
Central Retinal Vein Occlusion with Macular Edema
Diabetic Macular Edema
Diabetic Retinopathy

Interventions

DRUG: FYB203 2 mg (0.05 mL of 40 mg/mL)

Sponsor

Formycon AG